Anticorps Monoclonal Anti-cytokeratine Peptide 19 produit dans la souris, clone A53 - B/A2, supernatant de la culture tissulaire

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is also suitable: for immunoblotting, for immunocytochemistry, for immunofluorescence, as a marker of premalignant lesions of the oral epithelium, to label cytokeratin in formalin-fixed or Carnoy-fixed, paraffin embedded tissue and in frozen sections of human tissue, to label simple epithelia and basal cells of noncornifying stratified squamous epithelia.

Monoclonal Anti-Cytokeratin Peptide 19 antibody produced in mouse is suitable for microarray and indirect immunofluorescence at a dilution of 1:50 using formalin-fixed, paraffin-embedded and human tissue sections.

Biochem/physiol Actions

Monoclonal anti-cytokeratins are specific markers of epithelial cell differentiation and have been widely used as tools in tumor identification and classification.

Keratin, type I cytoskeletal 19 (40kDa protein) is also known as cytokeratin-19 (CK-19) or keratin-19 (K19). It is encoded by the KRT19 gene in humans. Keratin 19 is a type I keratin. Keratins are intermediate filament-forming proteins that provide mechanical support and perform a variety of additional functions in epithelial cells. K19 is expressed in a subset of hepatocellular carcinomas (HCC) with poor prognosis and is considered as a biliary/hepatic progenitor cell (HPC) marker. It is also a predictor of poorer prognosis for patients with human lung squamous cell carcinoma (SCC).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-Cytokeratin Peptide 19 (mouse IgG2a isotype) is derived from the A53-B/A2 hybridoma produced by the fusion of mouse myeloma cells and splenocytes from BALB/c mice immunized with mammary human carcinoma cell line MCF-7. Monoclonal Anti-Cytokeratin Peptide 19, known as clone A53-B/A2, or clone No. Ks 19.1, reacts with the rod domain of human cytokeratin peptide 19 (40 kDa), a cytoskeletal protein restricted to epithelial and carcinoma cells. Cytokeratin 19 is a member of the type I acidic subfamily. It is differentially expressed in various human tissues.

Immunogen

human mammary carcinoma cell line MCF-7.

Specificity

Also cited as clone no. KS 19.1, the antibody reacts with the rod domain of cytokeratin peptide 19, a cytoskeletal protein restricted to epithelial and carcinoma cells. Species cross-reactivity is low or absent. The antibody labels simple epithelia and basal cells of non-cornifying stratified squamous epithelia. It is a useful tool in discriminating simple carcinomas from those of different origin and for carcinoma subtyping. This antibody has also been shown to be a marker of pre-malignant lesions of the oral epithelium.